References to clinical trials, body-weight outcomes, glucose-related measures, or other human endpoints are not claims about this product and do not indicate that it is intended for human or animal use
Though anecdotal reports are common, large-scale human trials remain limited, highlighting the need for further scientific validation
Contrarily, when there is a peptide carrier, far more investigated and commonly implied angiogenic standard growth factors in the growth factor healing concept (Tarnawski and Ahluwalia, 2012
Participants taking liraglutide also achieved a 5.5% total body weight change compared with placebo over the 48-week study period
more is not always better, and your injection is already supplying a robust dose
10.1038/s41467-023-37874-2 11 BurkhartD